Roche’s Vabysmo to offer ‘fierce competition’ to Regeneron’s Eylea
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Summary : Roche’s Vabysmo is having a strong start with doctors, but it has a long way to go if it wants…
Keypoints USFDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early NSCLC Tecentriq treatment reduced the risk of disease recurrence…